Insys Therapeutics (INSY) Misses Q2 EPS by 10c; DEA Quota Granted

Insys Therapeutics (NASDAQ: INSY) reported Q2 EPS of $0.10, $0.10 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $77.6 million versus the consensus estimate of $74.06 million.

DEA Quota Granted

On August 5, 2015, Insys received a DEA Quota of 200 kg for the bulk manufacture of pharmaceutical CBD for its new Oakmont facility in Round Rock, Texas, for the remainder of 2015. The new quota augments the 90 kg Quota for 2015 at the Company's Paloma facility, bringing its aggregate Quota for 2015 to 290 kilos.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Haemonetics signs non-exclusive supply deal with CSL Plasma
• Enhanced Group plans AI health platform launch in 2026
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance